Immunotherapies (IT) have successfully entered the clinical arena of oncology. From a neuro-oncological perspective, IT has not been a breakthrough, yet, but first clinical trials show immunotherapeutic efficacy. Immunotherapeutic modalities are manifold, including vaccinations of peptides, of ribonucleic acids, and cellular therapies. Essential for all above-mentioned modalities is the selection of a suitable tumor-specific target to be attacked by the immune system. The applicant has shown that IDH1R132H, a frequently altered protein in brain tumors, is recognized by T helper cells and suitable for IT. Here, with the help of single cell immune receptor sequencing, Dr. Bunse aims at understanding intratumoral mechanisms of tumor-reactive T helper cells to improve IT for brain tumor patients.

Here you can get further information.